

主管 北京市药品监督管理局
主办 北京药学会

名誉主编 于德泉 王汝龙
主编 李大魁 翟所迪
社长 薛立宁
副主编 胡欣 崔一民 赵荣生
梅丹 钟武 赵志刚

本期执行主编 翟所迪
编辑部主任 马文利

编辑出版 《临床药物治疗杂志》社
地址 北京市朝阳区北三环中路2号(100120)
电话 86(10)6417 8704-301/302
邮箱 zazhi@vip.sina.com
网址 http://www.lcywzlzz.com

广告经营许可证 京海市监广登字20190024号
印刷 北京万谦恒溢广告传媒有限责任公司

国内发行 北京报刊发行局
国内订阅 全国各地邮局
邮发代号 82-110
国外发行 中国国际图书贸易总公司
邮发代号 BM 1764
邮购 《临床药物治疗杂志》社
国内定价 每期18.00元 全年216.00元

2020年第18卷第2期2月出版

ISSN 1672-3384
CN 11-4989/R

2020年版权归《临床药物治疗杂志》社所有
除非特别声明

本刊法律顾问 北京市百瑞律师事务所

本刊电子版出版发行合作伙伴
中国知网 www.cnki.net
万方数据 www.wanfangdata.com.cn



目次

■ 指南与共识

- 关于医疗机构药学部门应对新型冠状病毒感染的肺炎的工作建议
(第二版)北京市药学会质量控制和改进中心 (1)
- 新型冠状病毒肺炎疫情下加快开展智慧药学服务的专家共识(第一版)
.....中国智慧药学联盟专家组 (4)

■ 综 述

- 新型冠状病毒的起源追溯与探讨陈国民 (10)
- 新型冠状病毒肺炎与传染性非典型肺炎特点及药物治疗的对比分析
.....朱愿超, 谭玲, 刘蕾, 李可欣, 齐文渊, 胡欣 (15)
- 新型冠状病毒肺炎的药物治疗方案及研究进展
.....鹿文渊, 王乔羽, 赵志刚 (24)
- 氯喹抗新型冠状病毒感染的临床药理学综述
.....么雪婷, 崔诚, 刘东阳, 李海燕 (30)
- 全国新型冠状病毒感染医院药理学防控策略与诊疗方案荟萃
.....周鹏翔, 杨丽, 赵荣生 (34)

■ 专家看法

- 新型冠状病毒感染疫情中 ACEI 的争议: 下结论还为时尚早
.....董淑杰, 翟所迪, 李子健, 张幼怡 (40)
- 利巴韦林在抗新型冠状病毒感染使用中的新观点冯穗芬, 魏毅 (43)
- 冠状病毒 RNA 聚合酶抑制剂——利巴韦林的构效关系分析
.....冯穗芬, 魏毅, 刘建辉 (46)

■ 未来药物

- 抗新型冠状病毒药物——瑞德西韦刘淑娟, 于芳, 何宇鹏, 李行舟 (50)

■ 最新药物

新型冠状病毒肺炎潜在治疗药物——洛匹那韦/利托那韦 苏铮, 樊士勇 (56)

■ 论 著

《新型冠状病毒肺炎诊疗方案(试行第六版)》中医学观察期患者的中成药治疗文献分析
..... 刘颖, 刘丽, 曹苗苗, 温剑, 周燊, 江华, 张妍, 赵荣生, 杨毅恒 (62)

■ 药物与临床

从药代动力学角度看利巴韦林的静脉输注 刘维, 于之恒, 谈志远, 吴紫阳, 翟所迪 (67)

利巴韦林在新型冠状病毒肺炎治疗中的应用及注意事项
..... 余敏, 胡静, 刘小华, 傅源源, 郭玉娇, 张吉, 邹颖, 罗璨, 孙尧 (71)

激素类药物在病毒性肺炎治疗中的应用与循证评价 武明芬, 陈瑞玲, 赵志刚 (80)

世界卫生组织推荐的免洗手消毒液的配制 王钰莹, 赵丽平, 曹明楠, 赵夕岚 编译, 段京莉 审校 (87)

■ 《临床药物治疗杂志》投稿须知 (90)

Responsible Institution

Beijing Medical Products Administration

Sponsor

Beijing Pharmaceutical Association

Honorary Editor-in-Chief

YU De-quan WANG Ru-long

Editor-in-Chief

LI Da-kui ZHAI Suo-di

Proprieter

XUE Li-ning

Deputy Editor-in-Chief

HU Xin CUI Yi-min ZHAO Rong-sheng

MEI Dan ZHONG Wu ZHAO Zhi-gang

Executive Editor-in-Chief

ZHAI Suo-di

Editorial Director

MA Wen-li

Edited and Published by

Clinical Medication Journal Agency

Address: No.2, North Third Ring Road, Chaoyang

District, Beijing 100120, China

Tel: 86 (10) 6417 8704-301/302

E-mail: zazhi@vip.sina.com

Website: http://www.lcywzlzz.com

Printed by

Beijing Wanqian Hengyi Advertising Media Co., Ltd.

Domestic Distributor

Beijing Post Office

Code No.82-110

Overseas Distributor

China International Book Trading Corporation

Code No.BM1764

Price: ¥18.00

2020 Vol.18, No.2

Publication Date Feb, 2020

ISSN 1672-3384

CN 11-4989/R

Copyright

2020 by the Clinical Medication Journal Agency

Legal Consultant

Beijing Bairui Law Firm

CONTENTS

■ Guidelines and Consensus

Recommendations on Hospital Pharmacy Departments Coping with Corona Virus

Disease 2019(2nd edition)

..... Beijing Pharmacy Center for Quality Control and Improvement (1)

Expert Consensus on Accelerating the Development of Intelligent Pharmaceutical

Care during the Epidemic of Corona Virus Disease 2019(1st edition)

..... Expert Panel of China Intelligent Pharmacy Alliance (4)

■ Reviews

Discussion on the origin of severe acute respiratory syndrome coronavirus 2

..... CHEN Guo-min (10)

Comparative analysis of characteristics and medications between corona virus disease 2019 and severe acute respiratory syndrome

..... ZHU Yuan-chao, TAN Ling, LIU Lei, LI Ke-xin, QI Wen-yuan, HU Xin (15)

Research progress on corona virus disease 2019 drug therapy

..... PANG Wen-yuan, WANG Qiao-yu, ZHAO Zhi-gang (24)

Clinical pharmacology progress of chloroquine in the treatment of corona virus disease 2019

..... YAO Xue-ting, CUI Cheng, LIU Dong-yang, LI Hai-yan (30)

A review on the pharmaceutical management, prevention, control and pharmacotherapy for corona virus disease 2019 in China

..... ZHOU Peng-xiang, YANG Li, ZHAO Rong-sheng (34)

■ Expert Opinion

Controversies on the use of ACEI in patients with corona virus disease 2019: too early to draw a conclusion

..... DONG Shu-jie, ZHAI Suo-di, LI Zi-jian, ZHANG You-yi (40)

The new ideas for potential use of ribavirin in treatment of corona virus disease 2019

..... FENG Sui-fen, WEI Yi (43)

Analysis on structure-activity relationship of corona virus RNA polymerase inhibitor: ribavirin

..... FENG Sui-fen, WEI Yi, LIU Jian-hui (46)

■ **Drugs in the Future**

A novel drug for the treatment of severe acute respiratory syndrome coronavirus 2—remdesivir

.....LIU Shu-juan, YU Fang, HE Yu-peng, LI Xing-zhou (50)

■ **New Drugs**

Potential therapeutic drug for corona virus disease 2019—lopinavir/ritonavirSU Zheng, FAN Shi-yong (56)

■ **Original Articles**

Literature analysis of Chinese patent medicine treatment in the observation period of Clinical Management of Corona Virus

Disease 2019(trial 6th edition)

..... LIU Ying, LIU Li, CAO Miao-miao, WEN Jian, ZHOU Shen, JIANG Hua, ZHANG Yan, ZHAO Rong-sheng, YANG Yi-heng (62)

■ **Drugs and Clinics**

Discussion on intravenous infusion of ribavirin from the pharmacokinetic perspectives

.....LIU Wei, YU Zhi-heng, TAN Zhi-yuan, WU Zi-yang, ZHAI Suo-di (67)

Application and precautions of ribavirin in corona virus disease 2019

..... YU Min, HU Jing, LIU Xiao-hua, FU Yuan-yuan, GUO Yu-jiao, ZHANG Ji, ZOU Ying, LUO Can, SUN Yao (71)

Application and evidence—based evaluation of corticosteroid in viral pneumonia

.....WU Ming-fen, CHEN Rui-ling, ZHAO Zhi-gang (80)

Guidance on local production: WHO—recommended handrub formulations

.....translated by WANG Yu-ying, ZHAO Li-ping, CAO Ming-nan, ZHAO Xi-lan, checked by DUAN Jing-li (87)